Pharmacological inhibition of the transcription factor PU.1 in leukemia

Iléana Antony-Debré, Ananya Paul, Joana Leite, Kelly Mitchell, Hye Mi Kim, Luis A. Carvajal, Tihomira I. Todorova, Kenneth Huang, Arvind Kumar, Abdelbasset A. Farahat, Boris A. Bartholdy, Swathi-Rao Narayanagari, Jiahao Chen, Alberto Ambesi-Impiombato, Adolfo A. Ferrando, Ioannis Mantzaris, Evripidis Gavathiotis, Amit K. Verma, Britta Will, David W. Boykin & 3 others W. David Wilson, Gregory M.K. Poon, Ulrich G. Steidl

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.

Original languageEnglish (US)
Pages (from-to)4297-4313
Number of pages17
JournalJournal of Clinical Investigation
Volume127
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Acute Myeloid Leukemia
Leukemia
Pharmacology
Myeloid Cells
Pentamidine
RNA Interference
Tumor Burden
Small Interfering RNA
Chromatin
proto-oncogene protein Spi-1
Therapeutics
Down-Regulation
Transplantation
Apoptosis
Survival
DNA
Growth
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., ... Steidl, U. G. (2017). Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation, 127(12), 4297-4313. https://doi.org/10.1172/JCI92504

Pharmacological inhibition of the transcription factor PU.1 in leukemia. / Antony-Debré, Iléana; Paul, Ananya; Leite, Joana; Mitchell, Kelly; Kim, Hye Mi; Carvajal, Luis A.; Todorova, Tihomira I.; Huang, Kenneth; Kumar, Arvind; Farahat, Abdelbasset A.; Bartholdy, Boris A.; Narayanagari, Swathi-Rao; Chen, Jiahao; Ambesi-Impiombato, Alberto; Ferrando, Adolfo A.; Mantzaris, Ioannis; Gavathiotis, Evripidis; Verma, Amit K.; Will, Britta; Boykin, David W.; Wilson, W. David; Poon, Gregory M.K.; Steidl, Ulrich G.

In: Journal of Clinical Investigation, Vol. 127, No. 12, 01.12.2017, p. 4297-4313.

Research output: Contribution to journalArticle

Antony-Debré, I, Paul, A, Leite, J, Mitchell, K, Kim, HM, Carvajal, LA, Todorova, TI, Huang, K, Kumar, A, Farahat, AA, Bartholdy, BA, Narayanagari, S-R, Chen, J, Ambesi-Impiombato, A, Ferrando, AA, Mantzaris, I, Gavathiotis, E, Verma, AK, Will, B, Boykin, DW, Wilson, WD, Poon, GMK & Steidl, UG 2017, 'Pharmacological inhibition of the transcription factor PU.1 in leukemia', Journal of Clinical Investigation, vol. 127, no. 12, pp. 4297-4313. https://doi.org/10.1172/JCI92504
Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation. 2017 Dec 1;127(12):4297-4313. https://doi.org/10.1172/JCI92504
Antony-Debré, Iléana ; Paul, Ananya ; Leite, Joana ; Mitchell, Kelly ; Kim, Hye Mi ; Carvajal, Luis A. ; Todorova, Tihomira I. ; Huang, Kenneth ; Kumar, Arvind ; Farahat, Abdelbasset A. ; Bartholdy, Boris A. ; Narayanagari, Swathi-Rao ; Chen, Jiahao ; Ambesi-Impiombato, Alberto ; Ferrando, Adolfo A. ; Mantzaris, Ioannis ; Gavathiotis, Evripidis ; Verma, Amit K. ; Will, Britta ; Boykin, David W. ; Wilson, W. David ; Poon, Gregory M.K. ; Steidl, Ulrich G. / Pharmacological inhibition of the transcription factor PU.1 in leukemia. In: Journal of Clinical Investigation. 2017 ; Vol. 127, No. 12. pp. 4297-4313.
@article{ddcfc917249d4bb89bad7049d860ce65,
title = "Pharmacological inhibition of the transcription factor PU.1 in leukemia",
abstract = "The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.",
author = "Il{\'e}ana Antony-Debr{\'e} and Ananya Paul and Joana Leite and Kelly Mitchell and Kim, {Hye Mi} and Carvajal, {Luis A.} and Todorova, {Tihomira I.} and Kenneth Huang and Arvind Kumar and Farahat, {Abdelbasset A.} and Bartholdy, {Boris A.} and Swathi-Rao Narayanagari and Jiahao Chen and Alberto Ambesi-Impiombato and Ferrando, {Adolfo A.} and Ioannis Mantzaris and Evripidis Gavathiotis and Verma, {Amit K.} and Britta Will and Boykin, {David W.} and Wilson, {W. David} and Poon, {Gregory M.K.} and Steidl, {Ulrich G.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1172/JCI92504",
language = "English (US)",
volume = "127",
pages = "4297--4313",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Pharmacological inhibition of the transcription factor PU.1 in leukemia

AU - Antony-Debré, Iléana

AU - Paul, Ananya

AU - Leite, Joana

AU - Mitchell, Kelly

AU - Kim, Hye Mi

AU - Carvajal, Luis A.

AU - Todorova, Tihomira I.

AU - Huang, Kenneth

AU - Kumar, Arvind

AU - Farahat, Abdelbasset A.

AU - Bartholdy, Boris A.

AU - Narayanagari, Swathi-Rao

AU - Chen, Jiahao

AU - Ambesi-Impiombato, Alberto

AU - Ferrando, Adolfo A.

AU - Mantzaris, Ioannis

AU - Gavathiotis, Evripidis

AU - Verma, Amit K.

AU - Will, Britta

AU - Boykin, David W.

AU - Wilson, W. David

AU - Poon, Gregory M.K.

AU - Steidl, Ulrich G.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.

AB - The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.

UR - http://www.scopus.com/inward/record.url?scp=85037141449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037141449&partnerID=8YFLogxK

U2 - 10.1172/JCI92504

DO - 10.1172/JCI92504

M3 - Article

VL - 127

SP - 4297

EP - 4313

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -